Overcoming Mycobacterium Tuberculosis Drug Resistance: Novel Medications
and Repositioning Strategies
- Rohan Samir Sachan

Abstract
Mycobacterium tuberculosis is a bacterium that causes tuberculosis, a
disease that affects millions of people worldwide. This bacterium is
considered a formidable multidrug-resistant pathogen due to its ability
to resist numerous antibiotics. The development of Mycobacterium drug
resistance is attributed to both innate and acquired mechanisms.
Previously, rifampin was thought to be an effective medication for
treating tuberculosis infections, but bacteria quickly developed
resistance to it. This highlighted the urgent need for new medications
to combat this bacterium. Fortunately, numerous other medications were
already on the market that had not been previously considered for
treating tuberculosis infections. Furthermore, researchers have proposed
several novel medications that are currently undergoing clinical
studies. To improve the efficacy of these drugs' mode of action, it is
suggested that researchers focus on identifying unique target sites in
the bacterium during the drug development process. This approach can
help overcome the challenges posed by Mycobacterium drug resistance. In
this review article, much of the focus is placed on the features of
novel drug resistance exacerbated in Mycobacterium tuberculosis.
Additionally, potential medications that are being repositioned or
developed from novel sources are also discussed. The ultimate goal of
this research is to find effective treatments for tuberculosis that can
overcome the challenges posed by Mycobacterium drug resistance